Alpha Emitter Compositions With Acid-Cleavable Tumor Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug conjugates for tumor treatment are often dependent on tumor-specific epitopes, ineffective in hypoxic environments, and costly, necessitating improved compositions and methods for targeted delivery of alpha emitters.
Innovation Solution
Development of alpha-emitter-conjugated compounds with a cleavable coupling moiety that preferentially targets the acidic tumor microenvironment, using chelators and linkers that are stable in circulation but cleavable under acidic conditions to enhance alpha emitter concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-drug conjugates are used to target tumor cells, then target specificity is improved, but the approach becomes dependent on target specificity and is typically not suitable where a tumor specific epitope is not readily available
Solution Approach 1:
The patent uses albumin as an intermediary carrier protein that is not tumor-specific but is widely expressed and taken up by tumor cells through general nutrient transport mechanisms. This intermediary approach allows alpha emitter delivery without requiring tumor-specific epitopes, resolving the contradiction between target specificity and adaptability.
Solution Approach 2:
Albumin serves as a universal delivery vehicle that can be taken up by various tumor cell types through common endocytic pathways, making the therapy applicable across different cancer types without requiring tumor-specific targeting mechanisms.
2Ease of operation
If doxorubicin is modified with maleimidocaproyl hydrazone to couple to albumin, then albumin acts as carrier protein for nutrients and is readily taken up into the tumor microenvironment, but the clinical trial with modified doxorubicin (aldoxorubicin) as a cytotoxic agents did not show a significant increase in progression free disease
Solution Approach 1:
The patent changes the payload from conventional cytotoxic drugs like doxorubicin to alpha emitting radionuclides (e.g., 225Ac, 211At, 212Pb, 213Bi). This parameter change in the therapeutic agent type, while maintaining the albumin carrier and hydrazone linker system, aims to achieve both effective tumor uptake and improved clinical outcomes through the high linear energy transfer and short range of alpha particles.
3Reliability
If nanoparticle albumin-bound paclitaxel (abraxane) is administered, then it preferentially accumulates in breast cancer tumor tissues and is notably effective in at least some cases, but the preparation of abraxane is not trivial, and the cost for abraxane compared to paclitaxel alone is substantially higher
Solution Approach 1:
The patent uses albumin, a natural protein that is relatively inexpensive and readily available, as the carrier compared to the complex nanoparticle formulation required for abraxane. The albumin-hydrazone-alpha emitter conjugate simplifies the manufacturing process while maintaining targeted delivery effectiveness.
4Object-affected harmful factors
If alpha emitters are coupled to antibodies to deliver localized therapy, then localized therapy is achieved, but the approach is generally dependent on target specificity and is typically not suitable where a tumor specific epitope is not readily available
Solution Approach 1:
The patent replaces the antibody intermediary with albumin as the carrier protein. Albumin serves as a non-specific intermediary that is universally taken up by tumor cells through general endocytic pathways, enabling alpha emitter delivery without requiring tumor-specific epitopes while maintaining localized therapy through tumor-selective accumulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances alpha emitter delivery to tumors, independent of hypoxia, with potential for increased efficacy and reduced toxicity by localized release within the tumor microenvironment.
Implementation Method 1
the chelator portion chelates the alpha-emitter
Implementation Method 2
the coupling moiety is preferentially cleavable in an acidic tumor microenvironment
Data Source
AI summary
Compositions, methods, and uses of an alpha emitter are provided in which the alpha emitter is coupled to carrier protein via a cleavable coupling moiety. The coupling moiety is preferably cleavable in an acidic tumor microenvironment, and as such will enrich the alpha emitter upon cleavage within the tumor microenvironment.